TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03858075
Drug: BLU-782
Normalized name: Blu-Kote
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules
Study: NCT03858075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules
Study: NCT03858075
Drug: BLU-782 taken with food
Normalized name: Blu-Kote
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules
Study: NCT02651623
Drug: Drug - Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 14 days
Study: NCT01260987
Drug: Conventional photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy using methyl-aminolevulinate and red light (37 J/cm2)
Study: NCT01260987
Drug: Fractional CO2 laser assisted PDT
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment with fractional CO2 laser before methyl-aminolevulinate PDT
Study: NCT04083872
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: D744 Cap. 1 Cap., single oral administration under fasting condition
Study: NCT04083872
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fasting condition
Study: NCT01000051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day, orally for 8 weeks.
Study: NCT00726115
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03732248
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert drug
Study: NCT00079105
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment
Study: NCT00079105
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment
Study: NCT00733824
Drug: AMD3100
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01166984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of normal saline (0.9% sodium chloride) administered over approximately 10 minutes
Study: NCT01840592
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01351129
Drug: Formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150-mg modified release capsule, short duration (single dose)
Study: NCT01351129
Drug: Formulation 3
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150-mg modified release capsule, long duration (single dose)
Study: NCT03246009
Drug: rHSA/GCSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: single injection-1.8mg
Study: NCT03246009
Drug: rHSA/GCSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: single injection-2.1mg
Study: NCT03246009
Drug: rHSA/GCSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: single injection-2.4mg
Study: NCT03246009
Drug: rHSA/GCSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple injection-1.8mg
Study: NCT03246009
Drug: rHSA/GCSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple injection-2.1mg
Study: NCT03246009
Drug: rHSA/GCSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple injection-2.4mg
Study: NCT01785602
Drug: QAW039
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT01785602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT03380039
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is used for lymphodepletion.
Study: NCT03212586
Drug: BAY1902607
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of BAY1902607; single dose administration; different dosage forms (redosing of BAY1902607 at dose group 4 with different formulations; redosing of BAY1902607 solid formulation at dose group 4 together with food)
Study: NCT03212586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of Placebo; single dose administration; different dosage forms (redosing of Placebo at dose group 4 with different formulations; redosing of Placebo solid formulation at dose group 4 together with food)
Study: NCT02360618
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Group Description
Study: NCT01511887
Drug: Oral Ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
Study: NCT00876317
Drug: Etoricoxib 60 mg
Normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg per oz per day for 14 days
Study: NCT00876317
Drug: Etoricoxib 90 mg
Normalized name: etoricoxib 90 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg per oz for 14 days
Study: NCT01544972
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
Study: NCT01544972
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
Study: NCT00003380
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00656253
Drug: Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months period of Herbal Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
Study: NCT00656253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months period of placebo plus 1 month period without placebo
Study: NCT00448058
Drug: GSK372475
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily administration during the 10-week treatment phase
Study: NCT00448058
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily administration during the 10-week treatment phase
Study: NCT02598349
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concomitant oral chemotherapy, capecitabine 1000mg by mouth twice daily, 5 days a week (M-F) on radiation days only.
Study: NCT00841126
Drug: Magnesium iron hydroxycarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.
Study: NCT00841126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
Study: NCT00653224
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg daily (matching oral tablet) for 14 days
Study: NCT04771741
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg once daily, beginning post-op day 4
Study: NCT01360034
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin: 50 mg vo as a single dose upon admission and then 25 mg vo every 6 hours for 48 hours.
Study: NCT02573324
Drug: Placebo for ABT-414
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion (IV)
Study: NCT01455883
Drug: ITCA 650 60 mcg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: exenatide in DUROS
Study: NCT00785226
Drug: RDEA119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total daily doses of RDEA119 from 10 mg/day to 100 mg/day
Study: NCT02564471
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA approve dosing schedule
Study: NCT01595516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsule to be taken by mouth once per day for 12 weeks
Study: NCT01677195
Drug: ACCS100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
Study: NCT01677195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is calcium carbonate, USP. This calcium mineral does not absorb mycotoxins, specifically aflatoxin and fumonisin. This mineral has approximately the same physical appearance as active test article.
Study: NCT01312909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo for twelve weeks,follow-up through Week 52
Study: NCT03540901
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3100m
Study: NCT00659646
Drug: gentamicin-collagen sponge and levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.
Study: NCT00509197
Drug: Placebo (sham inhaler)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01513772
Drug: Normal saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline(guess as 4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
Study: NCT02086591
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01774903
Drug: TTS-fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TTS-fentanyl patches releasing drug at the rate of 12.5 microgram (µg) per hour for 3 days. The patches will be replaced every 3 days until 30 days.
Study: NCT02309385
Drug: Prednisolone Acetate (1%) Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01400594
Drug: HTU-520 Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine hydrochloride patch
Study: NCT03285646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) every 4 weeks (Q4W)
Study: NCT03599427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administrated at induction of anesthesia and at the end of surgery (0.075 ml/kg)
Study: NCT02984397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02870218
Drug: Smoking research cigarettes with e-cigarette
Normalized name: E-Z Scrub with Ultradex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.
Study: NCT01421810
Drug: rhCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mcg IV
Study: NCT00801684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.
Study: NCT00801684
Drug: TrIP-2D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
Study: NCT00801684
Drug: TrIP-2SS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
Study: NCT00801684
Drug: TrIP-2D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
Study: NCT02691858
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg/kg with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
Study: NCT00343187
Drug: ACZONE (dapsone) Gel, 5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00035906
Drug: DEX PS DDS®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02113020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral admininstration of Placebo
Study: NCT00767624
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
Study: NCT03050086
Drug: BPX-04 1% minocycline topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily administration of topical minocycline gel to face
Study: NCT03050086
Drug: BPX-04 2% minocycline topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily administration of topical minocycline gel to face
Study: NCT03050086
Drug: BPX-04 vehicle topical gel
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily administration of topical minocycline gel to face
Study: NCT00491686
Drug: AZD6765
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT01595620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: small amount of alcohol with no THC, administered over 10 minutes
Study: NCT00778830
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan will be administered intravenously at a dose of 180 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil will be administered intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
Study: NCT00131287
Drug: Extract of Agaricus blazei Murill
Normalized name: Agaricus blazei whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02029924
Drug: Humalog®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)
Study: NCT00420680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
Study: NCT03063827
Drug: OnabotulinumtoxinA 200 UNT
Normalized name: onabotulinumtoxinA 200 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient in the treatment arm received a single injection of onabotulinumtoxinA 200 UNT to the detrusor muscle at 20 sites of the bladder body.
Study: NCT00778830
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin will be administered intravenously at a dose of 100 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil administration intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
Study: NCT03843359
Drug: GSK3745417
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3745417 will be administered.
Study: NCT01767116
Drug: ABT-450/r/ABT-267, ABT-333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Study: NCT02209324
Drug: ASP2151
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03083288
Drug: [18F]FluorThanatrace
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]FluorThanatrace is a radiotracer for PET/CT
Study: NCT01455675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 70 ml gargling solution, once daily
Study: NCT00312507
Drug: Bovine Lipid Extract Surfactant (administered by lavage)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00312507
Drug: Bovine Lipid Extract Surfactant (administered by bolus)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03541980
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen
Study: NCT03541980
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline volume equivalent
Study: NCT01728467
Drug: RVX000222
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
Study: NCT01728467
Drug: Placebo, RVX000222
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
Study: NCT03783559
Drug: chemotherapy±target therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy±target therapy
Study: NCT01391117
Drug: placebo.
Approvals — FDA: no, EMA: no, PMDA: no
Description: panel 1: 2 participants receive placebo at a q24h regimen.
Study: NCT01391117
Drug: placebo.
Approvals — FDA: no, EMA: no, PMDA: no
Description: panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
Study: NCT01391117
Drug: TMC649128.
Approvals — FDA: no, EMA: no, PMDA: no
Description: panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
Study: NCT01391117
Drug: placebo.
Approvals — FDA: no, EMA: no, PMDA: no
Description: panel 2, arm 2: 2 participants receive placebo at a q24h regimen.
Study: NCT01391117
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
Study: NCT01391117
Drug: TMC649128
Approvals — FDA: no, EMA: no, PMDA: no
Description: panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
Study: NCT01391117
Drug: TMC649128.
Approvals — FDA: no, EMA: no, PMDA: no
Description: panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
Study: NCT01391117
Drug: TMC649128
Approvals — FDA: no, EMA: no, PMDA: no
Description: panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
Study: NCT01391117
Drug: TMC649128.
Approvals — FDA: no, EMA: no, PMDA: no
Description: panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
Study: NCT01391117
Drug: placebo.
Approvals — FDA: no, EMA: no, PMDA: no
Description: panel 2, arm 1: 2 participants receive placebo at a q12h regimen.
Study: NCT02041455
Drug: Melatonin and Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02041455
Drug: Melatonin and Amitriptylin
Normalized name: amitriptyline and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03384667
Drug: Maekmoondong-tang
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMDT is a Herbal medicine consist of six herbs.
Study: NCT03384667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The granules do not contain any active ingredients.
Study: NCT01259193
Drug: Sorafenib and Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sorafenib ,tablet,400mg Bid ,until patient can not tolerance Zoledronic Acid ,powder for injection,4mg per 3 week for 1 year
Study: NCT02203591
Drug: 3M CHG/IPA Prep C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
Study: NCT02203591
Drug: 3M CHG/IPA Prep CH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
Study: NCT02203591
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
Study: NCT04629664
Drug: FX-322
Normalized name: Prevail-FX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT03383588
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intrathecal fentanyl 10 mcg. Fentanyl (also spelled fentanil) is an opioid which is used as a pain medication and together with other medications for anesthesia.
Study: NCT03383588
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine injection is used along with emergency medical treatment to treat life-threatening allergic reactions caused by insect bites or stings, foods, medications, latex, and other causes. Epinephrine is in a class of medications called alpha- and beta-adrenergic agonists (sympathomimetic agents). It works by relaxing the muscles in the airways and tightening the blood vessels.
Study: NCT05801627
Drug: SAL067
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAL067 6mg(2 tablet) and Metformin ≥1500mg
Study: NCT05801627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablet) and Metformin ≥1500mg
Study: NCT00580905
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion of adenosine at a dose of 80 mcg/kg/min for 30 minutes.